Nebenwirkungen · Datroway
Datroway 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9–10
HOS-153444 · Präparat HOS-100992
9 l Including skin hyperpigmentation and skin discolouration. m Including dry skin and xerosis. n Including fatigue and asthenia. o Including amylase increased and hyperamylasaemia. p Infusion-related reaction includes as any reaction (infusion-related reaction, bronchospasm, chills, flushing, hypersensitivity, hypotension, pruritus, pyrexia, rash, maculo-papular rash, urticaria, wheezing) occurring within the same day as Datroway infusion. q No adverse reactions have been identified with a frequency of rare or very rare based on the currently available safety data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-30T15:20:00Z · SHA-256 2af2f3f5780300dcbd1cf2c5d2f2a45c37c2f1201a201c3988247b9015cd89e5 · Passage 74e5e08c0f6239685d1cf225958716fabb5c34ad578e40c5736a7b39c7ec8fcf · Zeichen 6978–7569 im Abschnitt